---
layout: post
title: "中国之江生物冠病药物完成临床前研究"
date: 2021-11-09T11:34:17.774Z
author: 联合早报
from: https://www.zaobao.com/realtime/china/story20211109-1211789
tags: [ 联合早报 ]
categories: [ 联合早报 ]
---
<!--1636481220000-->
[中国之江生物冠病药物完成临床前研究](https://www.zaobao.com/realtime/china/story20211109-1211789)
------

<div>
<p>中国生物科技公司之江生物旗下的冠病药物，已完成临床前研究。</p><p>据中国第一财经前天（7日）报道，这款双特异性抗体药物SYZJ001，是之江生物与参股公司上海三优生物共同组建的团队合作开发，是中国原创研发的抗冠病病毒治疗药物。</p><p>之江生物总经理吕力琅说，针对冠病病毒突变株临的床前研究显示，SYZJ001对各类突变株的中和效果都“非常好”，对德尔塔变种毒株也有“很好”的中和效果。</p><section id="imu"><div id="dfp-ad-imu1">        </div></section><p>吕力琅也说：“如果获得一期临床批件，我们已经做好了开展在人体的一期临床实验的准备。”</p>            <a href="https://subscribe.sph.com.sg/promotions/zbpe-3-months-99-cents-promotion/?utm_campaign=zbpe399&utm_medium=sph-publication&utm_source=zb&utm_content=subscribelink-free-endofarticle" target="_blank"><img class="view-desktop lazyload  " data-src="https://static.zaobao.com/s3fs-public/freemium_images/20210901/paywall_desktop-zbpe399_2.png?VersionId=dHEiGouxxZpWwWTJE04dyGyUN74JOU2z" alt style="width:100%;" pinger-seen="true" src="https://static.zaobao.com/s3fs-public/freemium_images/20210901/paywall_desktop-zbpe399_2.png?VersionId=dHEiGouxxZpWwWTJE04dyGyUN74JOU2z" referrerpolicy="no-referrer"></a>      <a href="https://subscribe.sph.com.sg/promotions/zbpe-3-months-99-cents-promotion/?utm_campaign=zbpe399&utm_medium=sph-publication&utm_source=zb&utm_content=subscribelink-free-endofarticle" target="_blank"><img class="view-mobile lazyload " data-src="https://static.zaobao.com/s3fs-public/freemium_images/20210901/paywall_mobile-zbpe399_2.png?VersionId=qZnBcIGCJvPR8A2IAZOZuOxdoGZDatiI" alt pinger-seen="true" src="https://static.zaobao.com/s3fs-public/freemium_images/20210901/paywall_mobile-zbpe399_2.png?VersionId=qZnBcIGCJvPR8A2IAZOZuOxdoGZDatiI" referrerpolicy="no-referrer"></a>
</div>
